Rani Therapeutics (RANI) Expected to Announce Earnings on Monday

Rani Therapeutics (NASDAQ:RANI) is projected to post its Q4 2025 results before the market opens on Monday, March 30th. Analysts expect the company to announce earnings of ($0.0475) per share and revenue of $5.00 million for the quarter. Parties can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Thursday, March 26, 2026 at 4:30 PM ET.

Rani Therapeutics Stock Performance

Shares of Rani Therapeutics stock opened at $1.13 on Monday. The company has a market capitalization of $137.31 million, a P/E ratio of -1.43 and a beta of 0.39. Rani Therapeutics has a 1 year low of $0.39 and a 1 year high of $3.87. The company’s fifty day moving average is $1.31 and its two-hundred day moving average is $1.30.

Wall Street Analysts Forecast Growth

RANI has been the subject of several recent research reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Rani Therapeutics in a research note on Monday, December 29th. HC Wainwright restated a “buy” rating and issued a $11.00 price target on shares of Rani Therapeutics in a research report on Friday, January 9th. Three investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $8.33.

Hedge Funds Weigh In On Rani Therapeutics

Institutional investors have recently bought and sold shares of the company. RA Capital Management L.P. purchased a new position in Rani Therapeutics during the 4th quarter worth $11,475,000. AWM Investment Company Inc. purchased a new stake in shares of Rani Therapeutics in the fourth quarter valued at about $8,775,000. SymBiosis Capital Partners LLC purchased a new stake in shares of Rani Therapeutics in the fourth quarter valued at about $8,505,000. Armistice Capital LLC acquired a new position in shares of Rani Therapeutics during the second quarter worth about $1,619,000. Finally, Siren L.L.C. acquired a new position in shares of Rani Therapeutics during the fourth quarter worth about $2,700,000. 30.19% of the stock is owned by institutional investors and hedge funds.

Rani Therapeutics Company Profile

Rani Therapeutics is a clinical-stage biopharmaceutical company developing oral delivery technologies for large-molecule drugs. The company’s proprietary RaniPill platform is designed to enable the gastrointestinal delivery of biologic therapies traditionally administered via injection. Through a swallowable capsule that autonomously deploys a microscopic injector in the small intestine, Rani aims to improve patient convenience and adherence for peptide and protein therapies, including insulin and other hormones.

Since its founding in 2012, Rani Therapeutics has advanced its lead programs through early-phase clinical trials, demonstrating proof-of-concept for oral insulin delivery.